In 2013, Chinese scientists unveiled the Regenovo bioprinter, one of the world’s most advanced 3D printers for human organs and tissues. Developed by Professor Xu Mingen of Hangzhou Dianzi University, this breakthrough positioned China at the forefront of regenerative medicine.
Regenovo Biotechnology was founded the same year to bring this innovation to market, aiming to build biomaterials, organs, and tissues for healthcare applications.
The Visionary Behind Regenovo: Professor Xu Mingen
- Professor of Bioengineering at Hangzhou Dianzi University.
- Research focus: Tissue engineering & regenerative medicine.
- Founder of Regenovo Biotechnology (2013).
- Mission: Create affordable and accessible bioprinting technology to solve the global shortage of transplantable organs.
Regenovo Biotechnology: Company Formation
Regenovo was co-founded in 2013 by Professor Xu Mingen and Shining 3D.
- Academic Excellence: University research, scientific credibility, peer-reviewed validation.
- Commercial Expertise: 3D printing manufacturing, marketing, global distribution.
With Series B funding, Shining 3D acquired 50% ownership, giving Regenovo strong financial and industrial backing.
Breakthrough Achievements
In 2014, Regenovo gained global attention after producing:
- Miniature liver samples in under an hour.
- 4–5 inch ear cartilage samples with viable cells.
These demonstrations proved:
- Cells can survive the printing process (90% survival rate).
- Functional tissue architectures are achievable.
- China’s bioprinting research rivals Western innovation.
Understanding 3D Bioprinting
What is Bioprinting?
Unlike plastic/metal 3D printing, bioprinting uses bio-inks made from:
- Living cells in hydrogels
- Biomaterials & polymers
- Growth factors & nutrients
The Regenovo Printing Process
- Digital Design: CT/MRI scans → 3D tissue models.
- Bio-ink Prep: Cells suspended in hydrogel.
- Printing: Layer-by-layer cell deposition.
- Maturation: Printed tissue grown in bioreactor.
- Quality Control: Sterility, structure, viability testing.
Technical Specifications
- Printhead Resolution: 80 microns.
- Cell Viability: ~90% post-printing.
- Advantages: Faster printing, reduced stress on cells.
- Challenges: Limited tissue complexity, vascularization difficulties.
Applications of Regenovo Bioprinting
Medical & Healthcare
- Drug Testing: Ethical alternative to animal testing.
- Personalized Medicine: Patient-specific tissues reduce rejection.
- Surgical Planning: Printed tissues aid complex procedures.
- Reconstructive Surgery: Cartilage, bone, and skin regeneration.
- Future Goal: Printing full organs (heart, liver, kidney).
Research & Education
- Disease Modeling: Study cancer, liver disease, neurological conditions.
- Toxicology: Chemical and cosmetic safety testing.
- Medical Training: Anatomical models for surgical practice.
Regenovo vs Organovo (China vs USA)
Similarities:
- Focus on functional tissues (liver, cartilage).
- Applications in pharma and regenerative medicine.
Regenovo’s Advantages:
- Lower development costs (China’s manufacturing edge).
- Government biotech support.
- Focus on practical, scalable applications.
Organovo’s Advantages:
- Earlier market entry.
- Strong IP portfolio in the US.
- Established pharma partnerships.
Continued Development: Bio-architect Series
After the first Regenovo printer, the company advanced with:
- Bio-architect Parrot Pro: High-precision, faster tissue printing.
- Bio-architect X (2017): First high-throughput bioprinter in China, enabling mass tissue production for drug testing.
Market Impact & Global Significance
- China’s Bioprinting Market Drivers: Aging population, organ shortage, government investment.
- Global Impact: Reduced costs, increased competition, accelerated innovation.
- Funding: Regenovo Biotechnology raised CN¥33M ($5M) in seed funding, enabling expansion.
Challenges Ahead
- Technical: Vascularization, tissue complexity, long-term viability.
- Regulatory: Clinical validation, safety testing, global approval processes.
- Ethical: Cell sourcing, equitable access, human enhancement concerns.
- Economic: High costs, insurance uncertainties, limited early adoption.
Future Prospects
- 5–10 Years: Widespread drug testing adoption, simple tissue repair (skin, cartilage).
- 10–20 Years: Complex organs-on-chip, reconstructive surgery applications.
- 20+ Years: Whole organ printing, ending organ shortages, transforming healthcare.
Conclusion: A New Era in Regenerative Medicine
The Regenovo Bioprinter, born in 2013 under Professor Xu Mingen’s leadership, marked China’s entry into world-class bioprinting technology. With ~90% cell viability and successful printing of liver and cartilage tissues, Regenovo proved that bioprinting is both practical and scalable.
While challenges remain in vascularization, regulation, and tissue complexity, Regenovo’s progress has positioned China as a true competitor in the global bioprinting race.
The dream of printing full human organs may still be decades away—but Regenovo has shown the world that the future of regenerative medicine is no longer science fiction.